The company has not filed an annual or quarterly report since its Q1 FY2020 10-Q, filed May 7, 2020. Its latest SEC filing is a CT ORDER from Feb 1, 2023.
10-Q for Q1 FY2020, filed May 7, 2020
The sections below describe the company as of the FY2019 annual report.
Sells Xerava, an intravenous antibiotic for complicated abdominal infections, through specialty distributors to hospitals and other treatment centers.
10-K for FY2019, filed Mar 12, 2020We are a biopharmaceutical company using our proprietary chemistry technology to create, develop and commercialize novel tetracyclines for…View ↗
In October 2018, we commenced sales of Xerava in the United States. We are commercializing Xerava in the United States using a small…View ↗
The Company’s product revenue consists of the sales of Xerava, which the Company began selling to customers in October 2018. The Company…View ↗
Specialty distributors buy Xerava and pay within 30 to 60 days; government agreements pay for services as performed, and licensing agreements can bring upfront fees, milestones, supply payments and royalties.
10-K for FY2019, filed Mar 12, 2020The Company’s product revenue consists of the sales of Xerava, which the Company began selling to customers in October 2018. The Company…View ↗
The Company is also subject to credit risk on its accounts receivable. The Company’s trade receivables from product sales have payment…View ↗
The Company’s government contract revenue has been derived from its subcontracts with CUBRC under the BARDA Contract, and the NIAID…View ↗
The Company has entered into an out-licensing agreement that is evaluated under Accounting Standards Codification, Topic 606 (“Topic 606”)…View ↗
$7.4M
10-K for FY2019, filed Mar 12, 2020
$7.4M ↗| Segment | Share | Revenue |
|---|---|---|
|
Product Revenue, net
|
48% |
Product Revenue, net, FY2019
$3.6M Sources
|
|
License and Collaboration Revenue
|
27% |
License and Collaboration Revenue, FY2019
$2M Sources
|
|
Government Revenue
|
24% |
Government Revenue, FY2019
$1.8M Sources
|
Tetraphase sells Xerava to specialty distributors, which resell it to hospitals and other treatment centers. Government-funded research work runs through contracts and subawards with research organizations.
No. It lost $70.1M in FY2019.
10-K for FY2019, filed Mar 12, 2020
10-K for FY2019, filed Mar 12, 2020
−$67.5MView ↗
10-K for FY2019, filed Mar 12, 2020
−$70.1MView ↗
10-K for FY2019, filed Mar 12, 2020
−$63.8MView ↗
10-Q for Q1 FY2020, filed May 7, 2020
−$12.1MView ↗
10-Q for Q1 FY2020, filed May 7, 2020
Open tableView ↗
8-K, filed Jul 29, 2020
As previously disclosed on June 24, 2020, Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) entered into an Agreement and Plan of Merger (the…View ↗
Shrank. Revenue fell 37% in 4 years, from $11.7M in FY2015 to $7.4M in FY2019, about 11% a year.
From clinical work to sales
The older report presents eravacycline and additional antibiotics as clinical-development programs; the latest report describes Xerava sales in the United States and says product development stopped, with pipeline candidates being offered for licensing.
10-K for FY2016, filed Mar 13, 2017 10-K for FY2019, filed Mar 12, 2020We are a clinical-stage biopharmaceutical company using our proprietary chemistry technology to create novel antibiotics for serious and…View ↗
We are conducting a global phase 3 clinical program for eravacycline called IGNITE (Investigating Gram-Negative Infections Treated with…View ↗
In January 2016, we initiated a phase 1 clinical trial of the IV formulation of TP-271, a fully synthetic fluorocycline being developed for…View ↗
In October 2018, we commenced sales of Xerava in the United States. We are commercializing Xerava in the United States using a small…View ↗
In addition to Xerava, we have also developed other fluorocycline antibiotic compounds, TP-6076 and TP-271, and TP-2846, a tetracycline for…View ↗
In June 2019, we announced a restructuring of our organization, including a 20% reduction in headcount, designed to focus our cash…View ↗
Competes with AstraZeneca, Merck, Pfizer, Allergan, and Melinta Therapeutics
10-K for FY2019, filed Mar 12, 2020We are selling Xerava as an IV antibiotic for use as a first-line empiric monotherapy for the treatment of cIAI. Xerava competes with a…View ↗
Loading...
